Cardiome CHF drug tanks in Phase II trials

Cardiome Pharma said Oxypurinol failed the efficacy test in a study of 405 congestive heart failure patients. The 24-week study yielded no statistically significant benefits over placebo, didn't increase the time between hospitalizations, and didn't improve quality of life. CEO Bob Rieder said he was disappointed in the "unequivocal negative outcome" but will review the data before deciding the fate of the program.

- read this report from for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.